Clinical trial
Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms…
NCT00409357 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00409357 |
|---|---|
| Title | Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia |
| Official title | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of SL77.0499-10 Once Daily Tablets in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia |
| Intervention type | Drug |
| Interventions | SL77.0499-10 (alfuzosin hydrochloride) |
| Enrollment | 473 |
| Start date | Nov 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Dec 8, 2006 |
| Last update posted | Oct 2, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: